Sintilimab in Patients with Previously Treated Metastatic Neuroendocrine Neoplasms

BACKGROUND: Neuroendocrine neoplasms (NENs) are a group of diseases that show high heterogeneity but have limited treatment options. This phase I study evaluated the safety and efficacy of sintilimab, anti-PD-1 monoclonal antibody, in treating advanced NENs. METHODS: We prospectively enrolled patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Ru, Li, Yi, Xu, Nong, Jiang, Hai-Ping, Zhao, Chuan-Hua, Liu, Rong-Rui, Shi, Yue, Zhang, Yao-Yue, Wang, Shu-Yan, Zhou, Hui, Xu, Jian-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355821/
https://www.ncbi.nlm.nih.gov/pubmed/35647908
http://dx.doi.org/10.1093/oncolo/oyac097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355821/
https://www.ncbi.nlm.nih.gov/pubmed/35647908
http://dx.doi.org/10.1093/oncolo/oyac097

Ejemplares similares